Pfizer (PFE) Says TALZENNA-XTANDI Combo Cut Progression Risk 52% in Phase 3 Prostate Cancer Trial

Pfizer and Astellas Pharma on May 30, 2026 reported that a combination of TALZENNA and XTANDI reduced the risk of disease progression or death by 52% compared to XTANDI alone in patients with homologous recombination repair (HRR)-mutated metastatic castration-sensitive prostate cancer (mCSPC). The Phase 3 TALAPRO-3 trial met its primary endpoint with statistical significance, positioning the dual therapy as a potential new standard of care. The data bolster Pfizer’s oncology pipeline at a time when it seeks to offset upcoming patent expirations. TALZENNA (talazoparib), a PARP inhibitor, and XTANDI (enzalutamide), an androgen receptor inhibitor, are already approved separately in other prostate cancer indications. Detailed results will be presented at an upcoming medical meeting. Analysts estimate the HRR-mutated mCSPC population could represent a multibillion-dollar market opportunity for the companies.